NASDAQ: SNTI - Senti Biosciences, Inc.

Rentabilität für sechs Monate: +14.45%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Senti Biosciences, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Senti Biosciences, Inc.

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.

weitere details
The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2022-06-09
ISIN US81726A1007
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.sentibio.com
Цена ао 3.84
Preisänderung pro Tag: -17.76% (3.66)
Preisänderung pro Woche: -23.99% (3.96)
Preisänderung pro Monat: -29.34% (4.26)
Preisänderung über 3 Monate: +39.35% (2.16)
Preisänderung über sechs Monate: +14.45% (2.63)
Preisänderung pro Jahr: +598.38% (0.431)
Preisänderung über 3 Jahre: -69.55% (9.885)
Preisänderung über 5 Jahre: 0% (3.01)
Preisänderung über 10 Jahre: 0% (3.01)
Preisänderung seit Jahresbeginn: -24.75% (4)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 9.51 1
P/BV 0.3641 10
P/E 0 0
EV/EBITDA -0.4243 0
Gesamt: 5

Effizienz

Name Bedeutung Grad
ROA, % -59.47 0
ROE, % -106.19 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.6122 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 2912.94 10
Rentabilität Ebitda, % 186.62 10
Rentabilität EPS, % 1244.77 10
Gesamt: 10
Weitere Details

Institutionen Volumen Aktie, %
NEA Management Company, LLC 4426151 9.67
8vc Gp I, LLC 2537558 5.55
ARK Investment Management, LLC 1969860 4.31
Vanguard Group Inc 707052 1.55
Intel Corporation 595665 1.3
Triatomic Management Lp 310533 0.68
Geode Capital Management, LLC 238406 0.52
Omega Fund Management, Llc 195792 0.43
Bridgeway Capital Management, Inc. 145000 0.32
Artal Group S.A. 55555 0.12



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Timothy K. Lu M.D., Ph.D. Co-Founder, CEO & Director 868.57k 1981 (44 Jahr)
Dr. James J. Collins Ph.D. Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director 58.5k 1966 (59 Jahre)
Dr. Kanya Rajangam M.D., Ph.D. President, Head of Research & Development and Chief Medical Officer 689.99k 1974 (51 Jahr)
Dr. Wilson Wong Ph.D. Scientific Co-Founder & Member of Scientific Advisory Board N/A
Ms. Yvonne Li M.B.A. Interim CFO, Treasurer & Principal Accounting Officer 1960 (65 Jahre)
Mr. Thomas P. Chung Vice President of Strategic Finance & Corporate Development
Ms. Dee Olomajeye Dragon Vice President of People Strategy & Culture

Adresse: United States, South San Francisco. CA, 2 Corporate Drive - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.sentibio.com